Ocaliva

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) — which is a frontrunner along with Gilead Sciences, Inc. (NASDAQ: GILD) in the non-alcoholic steatohepatitis drug development race — reported positive top-line results Tuesday for a late-stage study of its pipeline asset Ocaliva,...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reported top- and bottom-line beats last week that prompted two Street analysts to upgrade the stock. The Rating Goldman Sachs analyst Salveen Richter upgraded Intercept from Sell to Buy and more than tripled the price target from $46 to $157....

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) continued to sell off Friday in reaction to the U.S. Food and Drug Administration's letter to physicians warning them against the company's liver disease medicine called Ocaliva. One of the main takeaways from the FDA's letter is the absence of...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) lost around one quarter of their value Thursday and another 7 percent early Friday morning in reaction to a concerning U.S. Food and Drug Administration letter sent to doctors regarding its liver treatment product called Ocaliva for the...

The U.S. Food and Drug Administration sent a letter to doctors highlighting potential negative side effects from Intercept Pharmaceuticals Inc (NASDAQ: ICPT)'s liver disease medicine called Ocaliva. The FDA said in its letter that if it is incorrectly dosed in patients with moderate to severe...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) plummeted to a new 52-week low of $90.53 Tuesday morning before recovering a few dollars per share in reaction to a warning letter from the company to physicians. The letter cautioned against overdosing certain patients suffering from primary...

Credit Suisse's Alethia Young reiterated her Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ: ICPT) with a price target of $200.00. The reiteration came after Intercept's Octavia product passed FCC approval for treating Patients with PBC. "Ocaliva pricing of $69,350 was roughly in-line...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) rose 10 percent in the pre-market trading after FDA approved its drug Ocaliva to treat a rare liver disease. Ocaliva (obeticholic acid) is approved for the treatment of primary biliary cholangitis, previously known as primary biliary cirrhosis...

Morgan Stanley's Andrew Berens maintained Intercept Pharmaceutical Inc (NASDAQ: ICPT)'s Underweight rating with a price target of $80. The initiation came after the FCC granted accelerated approval to Intercept's Ocaliva product for treating patients with primary biliary cirrhosis (...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares are trading lower by $10.35 at $153.45 in Friday's session. It has been a volatile session for the issue and even more volatile if one takes into the price action if the after-hours and pre-market sessions. A little bit of history on the issue...